The biotech drug developer posted revenue of $44 million in the period, which did not meet Street forecasts. Five analysts surveyed by Zacks ...
News
- FibroGen: 3Q Earnings Snapshot
- Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates
... a PI3K-gamma inhibitor, in gynecological cancers at the 2020 San Antonio Breast Cancer Symposium (SABCS) Annual Meeting, December 8-11, ...
- Fate Therapeutics: 3Q Earnings Snapshot
The clinical-stage biotech company that develops stem cell treatments posted revenue of $7.6 million in the period, which also fell short of Street ...
- Xencor: 3Q Earnings Snapshot
The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $35.4 million in the period, which missed ...
- Ocular Therapeutix: 3Q Earnings Snapshot
The biotechnology company posted revenue of $5.9 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected ...